Akero Therapeutics reports Q1 EPS (90c), consensus (99c)

“In the first quarter of 2025, we reported an unprecedented statistically significant reversal of cirrhosis due to MASH following 96 weeks of treatment with EFX in the Phase 2b SYMMETRY study-a defining moment not only for Akero, but more broadly for the treatment of MASH,” said Andrew Cheng, president and CEO. “Cirrhosis had previously been viewed as an irreversible condition-managed by slowing progression to liver decompensation and treating complications, with effective treatment options limited to liver transplant. We believe the SYMMETRY week 96 results highlight the potential of EFX to transform the treatment of MASH, offering new hope to patients facing a disease with few meaningful treatment options. Publication of the SYMMETRY results in the New England Journal of Medicine underscores the importance of these results and strongly supports the continued evaluation of EFX in late-stage MASH-an effort we are currently undertaking as we advance our Phase 3 SYNCHRONY program, supported by more than $1.1B in cash, cash equivalents, and short- and long-term marketable securities on hand.”